These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27924061)

  • 1. The relationship between serum fibrosis markers and restrictive ventricular filling in patients with heart failure with reduced ejection fraction: A technetium-99m radionuclide ventriculography study.
    Lin YT; Lin YH; Wu XM; Ko CL; Yen RF; Chen YH; Hsu RB; Lee CM; Wang SS; Chen MF; Wu YW
    Oncotarget; 2017 Jan; 8(2):2381-2390. PubMed ID: 27924061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure.
    Cicoira M; Rossi A; Bonapace S; Zanolla L; Golia G; Franceschini L; Caruso B; Marino PN; Zardini P
    J Card Fail; 2004 Oct; 10(5):403-11. PubMed ID: 15470651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.
    de Denus S; Lavoie J; Ducharme A; O'Meara E; Racine N; Sirois MG; Neagoe PE; Zhu L; Rouleau JL; White M
    Can J Cardiol; 2012; 28(1):62-8. PubMed ID: 22104539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
    Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
    Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In patients with severe systolic dysfunction, only brain natriuretic peptide is related to diastolic restrictive pattern.
    Catuzzo B; Ciancamerla F; Bobbio M; Longo M; Trevi GP
    J Card Fail; 2003 Aug; 9(4):303-10. PubMed ID: 13680551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction.
    Poulsen SH
    Dan Med Bull; 2001 Nov; 48(4):199-210. PubMed ID: 11767125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?
    Collier P; Watson CJ; Voon V; Phelan D; Jan A; Mak G; Martos R; Baugh JA; Ledwidge MT; McDonald KM
    Eur J Heart Fail; 2011 Oct; 13(10):1087-95. PubMed ID: 21719449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The differences in the relationship between diastolic dysfunction, selected biomarkers and collagen turn-over in heart failure patients with preserved and reduced ejection fraction.
    Michalski B; Trzciński P; Kupczyńska K; Miśkowiec D; Pęczek Ł; Nawrot B; Lipiec P; Kasprzak JD
    Cardiol J; 2017; 24(1):35-42. PubMed ID: 27748500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma metalloproteinase-9 and restrictive filling pattern as major predictors of outcome in patients with ischemic cardiomyopathy.
    Bajraktari G; Miccoli M; Buralli S; Fontanive P; Elezi S; Metelli MR; Baggiani A; Dini FL
    Eur J Intern Med; 2012 Oct; 23(7):616-20. PubMed ID: 22939806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis.
    Lebedev DA; Lyasnikova EA; Vasilyeva EY; Babenko AY; Shlyakhto EV
    J Diabetes Res; 2020; 2020():6976153. PubMed ID: 33224989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis.
    Rossi A; Cicoira M; Golia G; Zanolla L; Franceschini L; Marino P; Graziani M; Zardini P
    Heart; 2004 Jun; 90(6):650-4. PubMed ID: 15145870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure.
    Flevari P; Theodorakis G; Leftheriotis D; Kroupis C; Kolokathis F; Dima K; Anastasiou-Nana M; Kremastinos D
    Am Heart J; 2012 Oct; 164(4):530-7. PubMed ID: 23067911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma BNP levels and left ventricular diastolic function as measured by radionuclide ventriculography in patients with coronary artery disease.
    Celiński R; Cholewiński W; Stefaniak B; Tarkowska A
    Nucl Med Rev Cent East Eur; 2004; 7(2):123-8. PubMed ID: 15968598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction.
    Campbell DJ; Mitchelhill KI; Schlicht SM; Booth RJ
    J Card Fail; 2000 Jun; 6(2):130-9. PubMed ID: 10908087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: a potential serum marker to evaluate cardiac autonomic control and sudden cardiac death.
    Lin YH; Lin C; Lo MT; Lin HJ; Wu YW; Hsu RB; Chao CL; Hsu HC; Wang PC; Wu VC; Wang SS; Lee CM; Chien KL; Ho YL; Chen MF; Peng CK
    Clin Chem Lab Med; 2010 Dec; 48(12):1821-7. PubMed ID: 20846104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.
    Martos R; Baugh J; Ledwidge M; O'Loughlin C; Murphy NF; Conlon C; Patle A; Donnelly SC; McDonald K
    Eur J Heart Fail; 2009 Feb; 11(2):191-7. PubMed ID: 19168518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction.
    Tromp J; van der Pol A; Klip IT; de Boer RA; Jaarsma T; van Gilst WH; Voors AA; van Veldhuisen DJ; van der Meer P
    Circ Heart Fail; 2014 May; 7(3):457-62. PubMed ID: 24647119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dobutamine-induced augmentation of left ventricular ejection fraction predicts survival of heart failure patients with severe non-ischaemic cardiomyopathy.
    Ramahi TM; Longo MD; Cadariu AR; Rohlfs K; Slade M; Carolan S; Vallejo E; Wackers FJ
    Eur Heart J; 2001 May; 22(10):849-56. PubMed ID: 11350094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue Doppler imaging adds incremental value in predicting exercise capacity in patients with congestive heart failure.
    Terzi S; Sayar N; Bilsel T; Enc Y; Yildirim A; Ciloğlu F; Yesilcimen K
    Heart Vessels; 2007 Jul; 22(4):237-44. PubMed ID: 17653517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.